244 related articles for article (PubMed ID: 30196935)
1. Economic Burden of Veno-occlusive Disease in Patients With B-cell Acute Lymphoblastic Leukemia in the United States.
Zhang X; Song X; Lopez-Gonzalez L; Jariwala-Parikh K; Romanov V; Cong Z
Clin Ther; 2018 Oct; 40(10):1711-1719.e1. PubMed ID: 30196935
[TBL] [Abstract][Full Text] [Related]
2. Defibrotide for Treatment of Severe Veno-Occlusive Disease in Pediatrics and Adults: An Exploratory Analysis Using Data from the Center for International Blood and Marrow Transplant Research.
Strouse C; Richardson P; Prentice G; Korman S; Hume R; Nejadnik B; Horowitz MM; Saber W
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1306-1312. PubMed ID: 27108694
[TBL] [Abstract][Full Text] [Related]
3. Defibrotide for Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome: Interim Results from a Treatment IND Study.
Richardson PG; Smith AR; Triplett BM; Kernan NA; Grupp SA; Antin JH; Lehmann L; Shore T; Iacobelli M; Miloslavsky M; Hume R; Hannah AL; Nejadnik B; Soiffer RJ;
Biol Blood Marrow Transplant; 2017 Jun; 23(6):997-1004. PubMed ID: 28285079
[TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness of Defibrotide in the Prophylaxis of Veno-Occlusive Disease after Pediatric Allogeneic Stem Cell Transplantation.
Pichler H; Horner K; Engstler G; Poetschger U; Glogova E; Karlhuber S; Martin M; Eibler W; Witt V; Holter W; Matthes-Martin S
Biol Blood Marrow Transplant; 2017 Jul; 23(7):1128-1133. PubMed ID: 28359910
[TBL] [Abstract][Full Text] [Related]
5. Earlier defibrotide initiation post-diagnosis of veno-occlusive disease/sinusoidal obstruction syndrome improves Day +100 survival following haematopoietic stem cell transplantation.
Richardson PG; Smith AR; Triplett BM; Kernan NA; Grupp SA; Antin JH; Lehmann L; Miloslavsky M; Hume R; Hannah AL; Nejadnik B; Soiffer RJ
Br J Haematol; 2017 Jul; 178(1):112-118. PubMed ID: 28444784
[TBL] [Abstract][Full Text] [Related]
6. Burden of illness associated with sinusoidal obstruction syndrome/veno-occlusive disease in patients with hematopoietic stem cell transplantation.
Cao Z; Villa KF; Lipkin CB; Robinson SB; Nejadnik B; Dvorak CC
J Med Econ; 2017 Aug; 20(8):871-883. PubMed ID: 28562132
[TBL] [Abstract][Full Text] [Related]
7. Prevention of veno-occlusive disease with defibrotide after allogeneic stem cell transplantation.
Chalandon Y; Roosnek E; Mermillod B; Newton A; Ozsahin H; Wacker P; Helg C; Chapuis B
Biol Blood Marrow Transplant; 2004 May; 10(5):347-54. PubMed ID: 15111934
[TBL] [Abstract][Full Text] [Related]
8. Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease: Final Results From the International Compassionate-Use Program.
Corbacioglu S; Carreras E; Mohty M; Pagliuca A; Boelens JJ; Damaj G; Iacobelli M; Niederwieser D; Olavarría E; Suarez F; Ruutu T; Verdonck L; Hume R; Nejadnik B; Lai C; Finetto G; Richardson P
Biol Blood Marrow Transplant; 2016 Oct; 22(10):1874-1882. PubMed ID: 27397724
[TBL] [Abstract][Full Text] [Related]
9. The Prophylaxis of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome With Defibrotide After Hematopoietic Stem Cell Transplantation in Children: Single Center Experience.
Karagun BS; Akbas T; Erbey F; Sasmaz İ; Antmen B
J Pediatr Hematol Oncol; 2022 Jan; 44(1):e35-e39. PubMed ID: 34966102
[TBL] [Abstract][Full Text] [Related]
10. The incidence of veno-occlusive disease following allogeneic hematopoietic stem cell transplantation has diminished and the outcome improved over the last decade.
Carreras E; Díaz-Beyá M; Rosiñol L; Martínez C; Fernández-Avilés F; Rovira M
Biol Blood Marrow Transplant; 2011 Nov; 17(11):1713-20. PubMed ID: 21708110
[TBL] [Abstract][Full Text] [Related]
11. Defibrotide for children and adults with hepatic veno-occlusive disease post hematopoietic cell transplantation.
Corbacioglu S; Richardson PG
Expert Rev Gastroenterol Hepatol; 2017 Oct; 11(10):885-898. PubMed ID: 28825848
[TBL] [Abstract][Full Text] [Related]
12. Two Cases of Veno-occlusive Disease/Sinusoidal Obstruction Syndrome After Thioguanine Treatment for Acute Lymphoblastic Leukemia.
Gruhn B; Brodt G; Mentzel HJ; Ernst J
J Pediatr Hematol Oncol; 2022 Mar; 44(2):e572-e575. PubMed ID: 33885036
[TBL] [Abstract][Full Text] [Related]
13. BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation.
Dignan FL; Wynn RF; Hadzic N; Karani J; Quaglia A; Pagliuca A; Veys P; Potter MN; ;
Br J Haematol; 2013 Nov; 163(4):444-57. PubMed ID: 24102514
[TBL] [Abstract][Full Text] [Related]
14. Defibrotide in the prevention and treatment of veno-occlusive disease in autologous and allogeneic stem cell transplantation in children.
Qureshi A; Marshall L; Lancaster D
Pediatr Blood Cancer; 2008 Apr; 50(4):831-2. PubMed ID: 18286502
[TBL] [Abstract][Full Text] [Related]
15. Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease after Autologous or Allogeneic Hematopoietic Stem Cell Transplantation in Children: a retrospective study of the Italian Hematology-Oncology Association-Hematopoietic Stem Cell Transplantation Group.
Faraci M; Bertaina A; Luksch R; Calore E; Lanino E; Saglio F; Prete A; Menconi M; De Simone G; Tintori V; Cesaro S; Santarone S; Orofino MG; Locatelli F; Zecca M
Biol Blood Marrow Transplant; 2019 Feb; 25(2):313-320. PubMed ID: 30266674
[TBL] [Abstract][Full Text] [Related]
16. Economic burden associated with adverse events of special interest in patients with relapsed Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia in the United States.
Zhang X; Song X; Lopez-Gonzalez L; Jariwala-Parikh K; Cong Z
Expert Rev Pharmacoecon Outcomes Res; 2018 Oct; 18(5):573-580. PubMed ID: 29923428
[TBL] [Abstract][Full Text] [Related]
17. Defibrotide for Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease Prophylaxis in High-Risk Adult Patients: A Single-Center Experience Study.
Picod A; Bonnin A; Battipaglia G; Giannotti F; Ruggeri A; Brissot E; Malard F; Médiavilla C; Belhocine R; Vekhoff A; Gueye MS; Lapusan S; Adaeva R; Isnard F; Legrand O; Baylatry MT; Joly AC; Labopin M; Duléry R; Mohty M
Biol Blood Marrow Transplant; 2018 Jul; 24(7):1471-1475. PubMed ID: 29477779
[TBL] [Abstract][Full Text] [Related]
18. The budget impact and cost-effectiveness of defibrotide for treatment of veno-occlusive disease with multi-organ dysfunction in patients post-hematopoietic stem cell transplant.
Veenstra DL; Guzauskas GF; Villa KF; Boudreau DM
J Med Econ; 2017 May; 20(5):453-463. PubMed ID: 28008770
[TBL] [Abstract][Full Text] [Related]
19. Combination of High-Dose Methylprednisolone and Defibrotide for Veno-Occlusive Disease in Pediatric Hematopoietic Stem Cell Transplant Recipients.
Gloude NJ; Jodele S; Teusink-Cross A; Grimley M; Davies SM; Lane A; Myers KC
Biol Blood Marrow Transplant; 2018 Jan; 24(1):91-95. PubMed ID: 28939456
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of defibrotide in the prevention of hepatic venooclusive disease among adult patients receiving allogeneic hematopoietic cell transplantation: A retrospective single center experience.
Kayikci O; Akpinar S; Tekgunduz E
Transfus Apher Sci; 2022 Feb; 61(1):103369. PubMed ID: 35120824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
